Andreessen Horowitz raises $9B across three funds: a $1.5B Bio Fund, a $5B Growth Fund, and a $2.5B Venture Fund
Andreessen HorowitzBen Horowitz
Context & Ripple Effects
This is the third data point in a clear fundraising escalation at Andreessen Horowitz. In 2019, on its tenth anniversary, it closed a $750M early-stage fund and a $2B later-stage fund, bringing its cumulative total to nearly $10B. Three years later, this single vintage of $9B — split into a $2.5B Venture Fund, a $5B Growth Fund, and a $1.5B Bio Fund — approaches what once took the firm a decade to raise.
The structure matters as much as the size: the Growth Fund alone outstrips the entire 2019 pair, and the dedicated Bio Fund formalizes life sciences as a standing pillar alongside software rather than an occasional bet. The trajectory held — by January 2026 the firm announced $15B+ across five new funds, with growth-stage capital again the largest slice.
First-order effects
Limited partners committing to these vehicles are underwriting a firm whose center of gravity has shifted decisively toward later-stage check-writing — the $5B Growth Fund is half the raise, versus a $2B later-stage vehicle being the exception back in 2019.
Bio-focused founders gain a committed, named pool of capital inside a firm previously known mainly for consumer and enterprise software, changing which pitches get a first meeting.
Second-order effects
Rival multi-stage firms face pressure to answer with comparable vintages, since a16z can now lead outsized growth rounds without syndication partners that smaller funds depend on.
Late-stage valuations absorb fresh supply: another $5B earmarked for growth-stage companies bids up competition for mature private rounds already contested by crossover investors.
Third-order effects
The pattern across 2019, 2022, and 2026 points to venture consolidating around a handful of branded multi-strategy platforms whose fund sizes compound each cycle, squeezing sub-scale firms out of competitive late-stage deals and pushing them downmarket.
A dedicated Bio Fund inside a generalist franchise foreshadows the sector-siloed mega-fund structure — separate pools per thesis under one platform — now standard among top-tier firms.
The trend: Top-tier venture firms are escalating into ever-larger multi-fund megaplatforms each vintage, with growth-stage capital taking the largest share and dedicated sector funds proliferating under one brand.
We're excited to announce that a16z has raised a fresh $9 billion to invest via our Venture, Growth, and Bio Funds. Thank you to our Limited Partners and many wonderful entrepreneurs who have made this possible. @bhorowitz has more on our website: https://a16z.com/...
@hkanji
Hussein Kanji on x
An insane amount of money. Net 4x-ing this is going to make some people very, very wealthy https://twitter.com/...
@jason
@jason on x
$270m a year... in fees 👀 They gonna take out public at this point https://twitter.com/...
@sriramk
Sriram Krishnan on x
Really thrilled to be partnering with the next generation of amazing founders and companies!
@sriramk
Sriram Krishnan on x
“We believe in the future and we bet the firm that way”. 💪💪💪💪 https://twitter.com/...
@zebulgar
@zebulgar on x
https://twitter.com/...
@harrystebbings
Harry Stebbings on x
Fuck! There was me thinking it was startups consuming cash quicker than ever. 🙄 https://twitter.com/...
@andrewchen
Andrewchen.Eth on x
Announcing a couple new funds at A16z 😎 https://twitter.com/...
@davidgeorge83
David George on x
Excited to share some firm news, and a mini-thread on @a16z Growth! 👀 https://a16z.com/...
@dhaber
David Haber on x
So grateful for the opportunity to partner with more amazing founders. It's time to build! 💪https://a16z.com/...
@geoffreywoo
@geoffreywoo on x
Incredible to watch @pmarca @bhorowitz @cdixon @vijaypande @ChrisLyons @alive_eth @DavidGeorge83 and the good people over at @a16z build. Innovation is happening across the entire sector of technology, including and especially capital. https://twitter.com/...
@aleximm
Alex Immerman on x
When friends ask what's different about working @a16z, I often say “we actually care about our firm values” One cultural value: “We believe in the future and we bet the firm that way” As @bhorowitz explains, that's why we raised $9B. Let's go!!! 🚀🚀 https://a16z.com/...
@pt
Parker on x
Has a media company ever raised this much before? https://twitter.com/...
@shaig
Shai Goldman on x
public markets down private market is on fire best time to be a Founder, $300B+ was invested in US startups in 2021 and there is a lot of dry powder available for 2022 https://twitter.com/...
@davidgeorge83
David George on x
We now have in excess of $10b+ AUM in @a16z Growth, and have partnered with 70+ companies in 100+ funding rounds. The goal remains the same as 3 years ago, and the opp'y in Growth thru public markets has never been greater...
@ericnewcomer
Eric Newcomer on x
As I reported Andreessen Horowitz is ready to do some public market investing https://www.newcomer.co/... https://twitter.com/...
@cindygallop
Cindy Gallop on x
Female/Black/of color/LGBTQ/disabled Biotech founders, get in there! #DiversityAndInclusion #ChangeTheRatio https://twitter.com/...
@vijaypande
Vijay Pande on x
1/ I'm thrilled to announce our fourth @a16z Bio Fund, bringing $1.5B of new capital to invest in the intersection of technology, life sciences & healthcare. https://a16z.com/...
@ktmboyle
Katherine Boyle on x
“One might ask: ‘Why invest $9B in a brand new set of technology companies?’ Our answer begins with one of the firm's core cultural values: We believe in the future and we bet the firm that way.” https://twitter.com/...
@bhorowitz
Benahorowitz.Eth on x
I am looking forward to helping our great entrepreneur partners build a better future. https://twitter.com/...
@davidu
@davidu on x
Big money to make big positive impacts. Let's go! 💯💯💯 https://twitter.com/...
@sarthakgh
Sar Haribhakti on x
They are doubling down on biotech and growth stage : https://a16z.com/...